CONBA(SH:600572)2023-10-27 16:00Revenue and Sales Performance - Revenue from the core product "Kang En Bei" brand Changyanning series reached 1.1 billion yuan, driven by increased brand promotion and marketing efforts[8] - Sales of "Kang En Bei" brand health food exceeded 400 million yuan, maintaining rapid growth through new product categories and channel expansion[8] - "Jin Kang Su Li" brand acetylcysteine effervescent tablets saw a 36% year-on-year sales increase[8] - Revenue for the first three quarters of 2023 reached 5.184 billion yuan, a year-on-year increase of 15.51%[33] - The traditional Chinese medicine and health products business generated revenue of 3.442 billion yuan in the first three quarters of 2023, accounting for 66.40% of total revenue, an increase of 4.29 percentage points year-on-year[34] - Self-care products business revenue reached 2.34 billion yuan in the first three quarters of 2023, a year-on-year increase of 23.68%[34] - Total revenue for the first three quarters of 2023 reached 5,184,266,884.99 RMB, a 15.5% increase compared to 4,488,268,722.41 RMB in the same period of 2022[48] - Revenue for the first three quarters of 2023 was 467,209,320.47, slightly down from 468,543,746.86 in the same period of 2022[72] Profit and Earnings - Net profit attributable to shareholders in Q3 2023 was 107.11 million yuan, a 532.29% increase year-on-year[14] - Net profit attributable to shareholders for the first nine months of 2023 was 623.24 million yuan, a 171.76% increase year-on-year[14] - Basic earnings per share for the first nine months of 2023 were 0.243 yuan, a 173.03% increase year-on-year[13] - Net profit attributable to shareholders of the listed company for the first three quarters of 2023 was 623.24 million yuan, a year-on-year increase of 171.76%[33] - Net profit attributable to parent company shareholders in the first three quarters of 2023 was 623,237,394.18 RMB, a 171.8% increase from 229,330,778.30 RMB in the same period of 2022[50] - Basic earnings per share for the first three quarters of 2023 were 0.243 RMB, a 173.0% increase from 0.089 RMB in the same period of 2022[50] - Net profit for the first three quarters of 2023 reached 974,847,499.92 RMB, a significant increase from 254,063,617.36 RMB in the same period of 2022[58] - Total comprehensive income for the first three quarters of 2023 was 699,887,141.20 RMB, a 130.1% increase from 304,164,855.70 RMB in the same period of 2022[50] - Total comprehensive income for the first three quarters of 2023 was 974,847,499.92 RMB, compared to 254,063,617.36 RMB in the same period of 2022[58] Financial Position and Assets - The company's total assets as of the end of Q3 2023 were 11.16 billion yuan, a 2.12% increase compared to the end of the previous year[13] - Total assets as of September 30, 2023, were 11,161,783,747.52 RMB, a 2.1% increase from 10,929,964,949.51 RMB as of December 31, 2022[48] - Total assets as of September 30, 2023: 11,161,783,747.52 RMB, an increase from 10,929,964,949.51 RMB at the end of 2022[46] - Total assets increased to 9,149,583,925.25 RMB as of September 30, 2023, compared to 8,248,072,073.79 RMB at the end of 2022[56] - Total assets increased to 9,149,583,925.25 as of September 30, 2023, compared to 8,248,072,073.79 at the end of 2022[69] Liabilities and Debt - The company issued 200 million yuan in short-term financing bonds with an annualized interest rate of 2.26% and a 180-day maturity[24] - Short-term borrowings decreased by 71.14%, mainly due to the repayment of maturing debts and optimization of the debt structure[38] - The company issued 400 million yuan in ultra-short-term financing bonds, leading to a 3035.32% increase in other current liabilities[38] - Short-term borrowings as of September 30, 2023: 207,156,833.35 RMB, a significant decrease from 717,733,669.45 RMB at the end of 2022[47] - The company issued 200 million RMB in ultra-short-term financing bonds on April 12, 2023, with an annualized interest rate of 2.75% and a maturity of 180 days[43] - The company completed the repayment of the 2023 first ultra-short-term financing bonds on October 9, 2023, with a total principal and interest repayment of 202,704,918.03 RMB[43] - Total liabilities as of September 30, 2023, were 3,643,808,920.61 RMB, a slight increase from 3,605,940,336.82 RMB as of December 31, 2022[48] - Total liabilities increased to 2,260,971,655.15 RMB as of September 30, 2023, compared to 1,948,801,705.76 RMB at the end of 2022[56] - Short-term borrowings decreased to 100,078,527.80 from 590,614,472.22 at the end of 2022[69] - Other payables increased to 1,673,078,520.20 from 1,160,639,969.00 at the end of 2022[69] Cash Flow and Liquidity - Operating cash flow for the first three quarters of 2023 was 658,417,306.12 RMB, a 26.8% increase compared to 519,268,865.96 RMB in the same period of 2022[52] - Cash received from sales of goods and services in the first three quarters of 2023 was 4,918,985,676.09 RMB, a 20.9% increase compared to 4,066,906,508.23 RMB in the same period of 2022[52] - Investment cash outflow in the first three quarters of 2023 was 586,381,700.11 RMB, a 60.7% increase compared to 364,826,903.99 RMB in the same period of 2022[52] - Cash and cash equivalents at the end of September 2023 stood at 2,140,028,244.30 RMB, compared to 1,844,641,962.75 RMB at the end of September 2022[68] - Net cash flow from financing activities was -758,822,252.32 RMB for the first three quarters of 2023, an improvement from -826,474,430.45 RMB in the same period of 2022[68] - Cash flow from operating activities was -22,699,668.75 for the first three quarters of 2023, an improvement from -28,629,512.01 in the same period of 2022[75] - Cash flow from investing activities was 490,609,179.32, significantly higher than 66,623,305.34 in the same period of 2022[75] - Cash flow from financing activities was -80,240,698.71, compared to -71,126,848.45 in the same period of 2022[75] - Net increase in cash and cash equivalents was 387,840,691.54, a significant improvement from -32,400,347.80 in the same period of 2022[75] Equity and Shareholder Information - Total number of ordinary shareholders at the end of the reporting period: 105,122[40] - Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. holds 535,777,040 shares, representing 20.85% of total shares[40] - Kanghong Group Co., Ltd. holds 223,431,171 shares, representing 8.69% of total shares[40] - Hu Jiqiang holds 133,579,085 shares, representing 5.20% of total shares, with 51,000,000 shares pledged[40] - Total equity attributable to parent company shareholders as of September 30, 2023, was 7,124,709,758.65 RMB, a 3.0% increase from 6,913,851,405.56 RMB as of December 31, 2022[48] - Total owner's equity (or shareholders' equity) rose to 6,888,612,270.10 RMB as of September 30, 2023, up from 6,299,270,368.03 RMB at the end of 2022[56] - Undistributed profits rose to 2,069,596,367.73 RMB as of September 30, 2023, up from 1,500,788,890.46 RMB at the end of 2022[56] Investments and Financial Instruments - The company transferred 7.84% equity of Jiangxi Zhenshiming Pharmaceutical Co., Ltd., resulting in a net profit of 86.72 million yuan[36] - Non-recurring gains and losses from the disposal of non-current assets amounted to 71.27 million yuan, mainly due to the transfer of equity in Zhenshiming Company[36] - The fair value change loss of financial assets was 66.86 million yuan, mainly due to the decline in the market value of Genor Biopharma shares[36] - Long-term equity investments grew to 6,071,498,745.82, up from 5,609,019,375.18 at the end of 2022[69] - Investment income surged to 1,014,996,916.07 in the first three quarters of 2023, compared to 265,554,181.02 in the same period of 2022[72] Expenses and Impairments - R&D expenses and equity incentive costs increased by approximately 30 million yuan year-on-year, impacting net profit[14] - Credit impairment losses for the first three quarters of 2023 were 1,871,858.83 RMB, down from 12,212,182.73 RMB in the same period of 2022[58] Other Financial Metrics - The company's weighted average return on equity for the first nine months of 2023 was 8.81%, an increase of 5.61 percentage points year-on-year[13] - Accounts receivable increased by 51.26%, mainly due to the growth in sales revenue[38] - Accounts receivable as of September 30, 2023: 1,441,951,041.98 RMB, an increase from 953,307,487.57 RMB at the end of 2022[46] - Monetary funds as of September 30, 2023: 2,244,231,034.18 RMB, a decrease from 2,468,031,909.97 RMB at the end of 2022[46] - Deferred income decreased to 2,936,700.00 RMB as of September 30, 2023, from 4,142,400.00 RMB at the end of 2022[56]